Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer
Title:
Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer
Author:
Fizazi, K. De Bono, J.S. Flechon, A. Heidenreich, A. Voog, E. Davis, N.B. Qi, Ming Bandekar, R. Vermeulen, J.T. Cornfeld, M. Hudes, G.R.